Diligence memo · auto-generated · as of July 2, 2026

Accure Acne, Inc.

Accure Acne, Inc. looks fair against its niche peers and is at-risk on financing cadence.

WatchOverdue for a raise versus sector cadence — could be a bridge, a down round, or distress. Watch for the next filing.

Businessfiled

Accure Acne, Inc. operates in Other Health Care, based in Boulder.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Accure Acne, Inc. has raised $29M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $22M on 2023-01-26.

Most recent recorded round closed around 2023-01-26.

Valuation (modeled)modeled

Provath models Accure Acne, Inc. at approximately $215M (range $50M–$505M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.41× the median modeled value of Series B Other Health Care companies in 2022–2024 (91 peers) — value vs value, same stage and era. Within the normal band (141% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 12 months.

Last raise 3.4 yr ago; this sector typically re-raises about every 14 months.

Past due for a raise versus sector cadence — watch for distress or a bridge.

The last round was 1.0× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 88% of Other Health Care peers (5377 compared).

Modeled value ranks above 88% of those peers.

Closest niche peers: Code Biotherapeutics, Inc., Candesant Biomedical, Inc., Artis Holdings, LLC, GIO Blood Ltd, Clarapath, Inc..

Peoplefiled

10 named people on file across officers, directors and signatories.

Risks & flagsmixed

Overdue for a raise versus sector norm — distress or bridge risk.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.